



Annual Report 2022



Manufacturing process as a key element

The Nanofactory allows continuous optimization of the manufacturing processes through the knowledge gained in the development phase: Production competence and know-how remain within the company.

Letter to Shareholders

InnoMedica's¹ fiscal year 2022 is characterized by major operational successes and by significant new challenges in the geopolitical market environment and the associated economic changes. The focus was on the continuation of the approval process for the oncology product at Swissmedic, the SMARTER study - a comparative study in collaboration with the Swiss Group for Clinical Cancer Research (SAKK) - as well as on the execution of the NEON study, InnoMedica's first clinical neurology study. With the progress in clinical research and a forward-looking expansion of production capacities at the Nanofactory, InnoMedica is laying the foundation for upcoming milestones.

Oncology approval procedure: The filing of the oncology product with Swissmedic already took place after the first clinical trial phase in order to obtain a more binding and detailed opinion from the regulator at an early stage and create favorable conditions for efficient clinical development with clear specifications for the novel nanotechnology. In the second quarter of 2022, InnoMedica received an initial response from Swissmedic to the application submitted in November 2021. In its response, Swissmedic in particular requested further clinical studies on pharmacokinetics and efficacy as well as additional documentation on quality, stability and the production methods. InnoMedica has already been able to address a number of fundamental aspects and present its viewpoint in an initial statement.

In a further opinion issued by Swissmedic in December 2022, the explanations provided and the data on clinical research and production processes were however still deemed insufficient. Although InnoMedica submitted the marketing authorization dossier in the category "known active ingredient with innovation", it has not yet been conclusively clarified to what extent the compound must be tested in a larger patient group and in yet more complex studies. The generation of additional clinical data involves considerable effort and correspondingly high costs. However, it would also create a solid basis for international approval, particularly in Europe, the USA and Japan. Finally, InnoMedica founded InnoMedica Deutschland GmbH in May 2022 as a first step towards the goal of internationalization and hired its first employee.

Oncology studies: Since the submission of the marketing authorization application in November 2021, InnoMedica has expanded the first clinical study in oncology into a comparative study and treated a total of 39 patients as of today. 9 of the patients have been enrolled in the SMARTER study, which will include a total of 14 patients. This study compares InnoMedica's product with another liposomal cancer therapy, which also contains the active ingredient doxorubicin, with regard to - among other things - side effects and the circulation of the active ingredient in the blood.

The planning of the TRACTION study, which will follow the SMARTER study, was concretized in the past fiscal year. In this study, InnoMedica itself will assume the role of the overall responsible party (study sponsor). The aim of this study with around 160 patients is a direct therapeutic comparison of InnoMedica's oncology product with standard chemotherapy in current clinical practice. The study protocol has been written by the InnoMedica team in collaboration with leading oncologists and is expected to be submitted to the Ethics Committee and to Swissmedic in spring 2023, once the contracts with the participating study centers are finalized.

Neurology studies: An important milestone for InnoMedica in fiscal year 2022 is the ongoing NEON study with InnoMedica's neurology product. The initial program of the Parkinson's study to determine the intravenously administered dose and to expand the number of patients with this defined dose was implemented within a few months. The study was extended after reaching the initially planned treatment duration and weekly treatment at the most recently defined dose can be continued for another four months for 11 study participants. InnoMedica furthermore submitted an additional amendment to strengthen the validity of the obtained study results with even longer treatment duration. InnoMedica plans to publish the initial study data in a scientific journal after submitting a further patent application. Meanwhile, a previously filed patent in the neurology field for the particularly important U.S. market was granted at the beginning of January 2023.

¹ InnoMedica hereinafter refers to the InnoMedica Group, consisting of InnoMedica Holding AG, InnoMedica Schweiz AG, InnoMedica Deutschland GmbH and YAMAZAKI-DDS Co., Ltd.

The conceptual planning of the subsequent study in neurology was largely completed by the end of 2022. The Parkinson's study was developed with the participating physicians. It will be based on a double-blind trial design with placebo control and will perform a comparative test of the product in a larger number of patients. This efficacy study is expected to generate solid data for the submission of a first marketing authorization application in Switzerland and later internationally. The start of this study with a budget of approximately CHF 7.5 million, however is dependent on the procurement of corresponding financial resources in a further capital increase.

The development progress achieved in neurology is reflected in the collaboration with Cure Parkinson's, a British organization dedicated to the development of treatments for Parkinson's disease. The aim of its iLCT initiative (international Linked Clinical Trials initiative) is to identify active substances that can potentially slow or even halt the progression of Parkinson's disease. As part of the initiative, InnoMedica shared recent trial results and planning documents with Cure Parkinson's. The lead assessors (Helen Matthews, Deputy CEO, CP; Dr Simon Stott, Director of Research, CP; Professor David K. Simon, iLCT Committee Chair) concluded from the information provided that InnoMedica's compound is an ideal candidate for further clinical testing and have confirmed their support for the neurology project in a Letter of Support.

As recognition of the innovative strength of InnoMedica's research and development projects, the Scientific Committee of the European Foundation for Clinical Nanomedicine (CLINAM) granted Dr. Stéfan Halbherr, Country Manager of InnoMedica Schweiz AG, the Dwarf Award in spring 2022. This prize is awarded annually to successful researchers in the field of nanomedicine. In previous years, for example, Prof. Chezy Barenholz, one of the inventors of the first nanomedical cancer drug, and Prof. Omid Farokhzad, the head of the world-renowned Farokhzad Lab at Harvard University, were honored with the award. InnoMedica's nanotechnology is based on the combination of an innovative delivery system with already known active ingredients. Its great potential was demonstrated in 2022 in the expansion of the application fields of existing formulations and the further development of pipeline products for various indications. Among other things, InnoMedica has generated new research results on amyotrophic lateral sclerosis (ALS) in pre-clinical studies together with a research group from the University of Bern, which will now be published in a scientific journal.

Expansion of production capacity: The start of the clinical trial with the neurology product had a significant impact on the production department. In the company's own Nanofactory in Marly near Fribourg, two products are now manufactured for clinical trials in accordance with Good Manufacturing Practice (GMP). To ensure product supplies for the extensive clinical trials as well as for future market launch, further progress was made in production scale-up in the new, larger clean room. Production volumes in oncology and neurology are currently in the range of 6- and 15-liter batches. Further scaling experiments and continuous optimization and automation of various process steps are ongoing. With considerable expansion opportunities available at the Marly Innovation Center, the site remains attractive for InnoMedica.

Challenge of capital market: In May 2022, InnoMedica again carried out a capital increase and raised CHF 6.8 million in capital. The lower volume of funds raised in comparison to previous years should be seen in context of the war in Ukraine and the resulting political and economic uncertainties. Capital raising for start-up companies experienced a sudden and significant drop worldwide. Due to limited financial resources, InnoMedica has been extremely cautious in recruiting, especially in the second half of 2022. The headcount across the company therefore remained stable compared to last year and consisted of 50 employees at the end of the year. At executive and middle management level, InnoMedica continues to have a stable and experienced management team with many long-standing employees, which ensures competent leadership.

Challenge of corporate communication: With InnoMedica's projects advancing and moving closer to market, corporate communications require adjustments in accordance with the requirements of the Therapeutic Products Act. In Switzerland, advertising of prescription-only medicinal products is prohibited in order to protect the general public and patients as well as to safeguard quality in medical decision-making. The regulations notably also affect the communication of clinical trial results to the general public, including investors, as this can easily be interpreted as advertising. However, InnoMedica continues to ensure that information is provided on project progress and successes in order to enable an informed investment decision..

Risk Assessment

Thanks to the progress of the products in the area of manufacturing and quality on the one hand as well as in clinical testing on the other, InnoMedica's risk pro-

file has further improved substantially. Certain risks exist in the context of market approval and the corresponding timing of initial sales. The conduct of clinical trials becomes more time-consuming and costly as the number of patients, the required production volumes, and the duration of recruitment phases increase.

On the one hand, the use of already approved active ingredients means that certain data do not have to be collected again for regulatory approval. On the other hand, however, one must take into account that an initial approval for an innovative liposomal nanoformulation poses significant challenges from a regulatory point of view - especially with regard to the planned market entry. This concerns the innovations in production, the status of their implementation in the GMP process as well as the reliability of scale-up for larger volumes and clinical data generation. Due to the expected market volume, there are further requirements in scale-up and in the validation of all process steps. InnoMedica has established production capacities for clinical products in oncology and neurology at the Marly site, thus ensuring the supply for patients participating in clinical trials. Delivery difficulties may result if production processes cannot be successfully implemented in their entirety - for example due to quality deficiencies of raw materials or external partners. However, thanks to its own site and qualified employees, InnoMedica has been able to mitigate these risks well.

In the course of its work in research and development, InnoMedica generates extensive technological and product-related knowledge and intellectual property, the loss of which has the potential to impair the successful marketing of InnoMedica's products. InnoMedica therefore invests extensively in safeguarding its in-house know-how through measures in infrastructure and information technology. In addition, InnoMedica pursues a program of patent protection for its products at the technology and application level.

Like its operational activities, InnoMedica's refinancing continues to be influenced by political, regulatory, and financial market factors. All financing options, in particular an initial public offering (IPO), are heavily dependent on the state of the financial markets and the risk appetite of potential investors, which may decrease in the current uncertain macroeconomic environment. In addition, InnoMedica is affected by supply chain disruptions and inflation as a result of the Covid pandemic and the Ukraine war. Impairments to operations have so far largely been avoided. As a young company with strong products and research capabilities, InnoMedica is well positioned to continue to address these challenges.

Outlook

InnoMedica will continue to prioritize the approval process for the oncology product in fiscal year 2023. Approval in the Swiss home market will support InnoMedica's goal of gradual internationalization. Furthermore, the execution of the extensive clinical TRACTION study with around 160 patients should enable a direct comparison with current standard therapies and a cooperation with numerous study physicians. However, such large-scale studies must always also be seen in the context of the correspondingly increased expenses for the study drugs, which InnoMedica would like to keep as low as possible.

In neurology, the priority in 2023 is the start of an efficacy study in addition to the completion of the NEON study and the publication of the data in a scientific journal. In addition to the dose finding, the extension of the NEON study will compare motor symptoms before the start of treatment with symptoms at later time points during the study by collecting motor scores according to internationally used scales (UPDRS). These first evaluations will be further investigated in an efficacy study in a larger patient group.

For the production of study compounds and preparation for the market, InnoMedica is pursuing further expansion of production capacity at the Nanofactory in Marly near Fribourg. To this end, experiments are currently being conducted to expand batch sizes and new, larger equipment is being tested. In oncology, it is planned to implement manufacturing of the product in 19-liter batches in summer 2023. For neurology, batch sizes of 50 liters will be implemented in the next scale-up step.

The implementation of the large-scale studies in both neurology and oncology is expensive. For the financing, a capital increase is again planned in the second quarter of 2023 in order to advance the planned studies as well as further scale-up projects in production as quickly as possible under our own steam. InnoMedica has prepared for a possible IPO and now meets all accounting requirements, but would like to wait for initial sales as well as a more stable global economic situation for an IPO. More detailed information on the planned capital increase will follow in spring 2023. As part of the public offering, investors have the opportunity to obtain a detailed picture of the current status of the projects and the planning by participating in investor events - an important prerequisite for a well-informed investment decision.

Given the clinical progress of InnoMedica's projects in both oncology and neurology, contacts with other companies regarding licensing and partnering became increasingly important in the financial year 2022.

Licensing may include, among other things, participation in the further clinical development of the compounds in return for access to current study results, and possibly also the assurance of distribution rights.

For fiscal year 2023, in a defensive scenario, it would be necessary to focus and move forward only in small steps. However, the interest of all stakeholders will rather be to show determination and not to lose time due to the favorable starting position. InnoMedica's current position has been carefully built up over ten years and has a solid foundation. Based on this, the necessary further steps can be taken with less risk today. This will result in not only valuable, consolidating knowledge, but also even more stable and efficient production. With the Nanofactory in Marly, InnoMedica has both innovation-creating laboratories with a full pipeline and efficient production in accordance with GMP as well as a highly motivated team.

The Board of Directors of InnoMedica Holding AG



Dr. Peter Halbherr
Chairman and Delegate
of the Board



Dr. Denis Bron
Vice Chairman
of the Board





Strong protection in addition to the patent

The company's proprietary nanotechnology and its applications are protected by patents. Moreover, due to in-house production, knowledge about the complex manufacturing process does not leave the company.

Financial Overview

InnoMedica ends the financial year 2022 with a solid financing situation, reflected in cash and cash equivalents of CHF 16,548,040 at year-end. The level of cash and cash equivalents corresponds to more than 150 percent of the financial resources of CHF -10,593,708 required by InnoMedica in 2022 (free cash flow). Thus, the prerequisites are in place for InnoMedica to successfully continue its operating activities in 2023. The focus in 2023 will be on achieving further milestones in the development of the drugs in oncology and neurology, confirming the promising clinical data of 2022 and bringing InnoMedica a big step closer to the commercialization of its drugs.

In spring 2022, InnoMedica was able to raise the necessary funds for drug development through a further capital increase. The capital increase took place in a challenging environment and under the influence of geopolitical and macroeconomic upheavals. The Ukraine conflict, rising inflation expectations as well as falling security prices led to uncertainty among investors and a more difficult financing situation for biotech companies. In particular, InnoMedica found that a successful IPO cannot be planned against the backdrop of developments on the capital markets. Considering the difficult environment, the capital increase was a notable success. InnoMedica received additional funds in the amount of CHF 6,860,514. This financing covered approximately 65 percent of the free cash flow in 2022 of CHF -10,593,708 and enabled InnoMedica to maintain a solid financing situation at the end of the year.

The amount of raised funds was significantly below the targeted amount of CHF 18,966,200 and InnoMedica's expected financing needs until break-even. InnoMedica reacted decisively to this situation, reviewed and prioritized planned investments and postponed the intended expansion of the workforce. Priority was given to the further successful development of the drugs and the acquisition of the necessary data from clinical trials. This goal was achieved in both oncology and neurology. The related operational activities are reflected in the development expenses, which were slightly higher at CHF 2,490,223 compared to CHF 2,214,766 in 2021, including the costs for the production of the drugs as well as the direct costs of the clinical trials that arise from patient treatment and trial management.

Further clinical development requires larger patient numbers in upcoming studies and thus larger produc-

tion volumes. InnoMedica is therefore continuing to pursue projects to increase production volumes at the Marly site. The investment for the next scale-up step has been completed and the implementation of pharmaceutical Good Manufacturing Practice (GMP) is well advanced. This will enable InnoMedica to make larger volumes available in a timely manner without major additional financial outlay. Investments in property, plant and equipment in 2022 thus amounted to only CHF 192,279 compared to CHF 538,071 in the previous year and was related to limited additional investments in clean room equipment and production automation.

The various conservative measures have made it possible to avoid a further increase in the annual loss compared to the previous year despite increased production volumes and expansion of the clinical trials. The net loss in 2022 amounts to CHF 10,501,695 and is largely unchanged compared to the net loss of CHF 10,371,890 in 2021. The increased development expenses are compensated by slightly decreased personnel expenses and other expenses.

InnoMedica took an important internationalization step in spring 2022 and founded a subsidiary in Germany. InnoMedica Deutschland GmbH has employed its first employee in Freiburg im Breisgau since October 2022. With the headquarter located within the European Union, the founding of this subsidiary enables InnoMedica to submit regulatory dossiers to the European Medicines Agency in its own name and to bring clinical studies to an international scope.

Cash and cash equivalents at year-end 2022 in the amount of CHF 16,548,040 are 18.4 percent lower than in the reporting year 2021 with CHF 20,281,234. The decrease results from necessary funds for operating expenses and investments (free cash flow) in the amount of CHF -10,593,708, which are offset by the additional funds raised from the capital increase in the amount of CHF 6,860,514. As a result of the capital increase, the nominal share capital of InnoMedica Holding AG was increased by CHF 16,856.30 and now amounts to CHF 1,433,955, divided into 14,339,550 shares with a par value of CHF 0.10 each. As in the previous year, in addition to the new shares, shares of existing shareholders were sold at a reduced price of CHF 10.18 in the capital increase of 2022. The subscription for one new share at CHF 40.70 included the free option to subscribe for one existing share at the reduced price. Once again, the selling existing shareholders, who have accompanied InnoMedica for more than 20 years but do

Key Items of the Financial Statements in CHF

Position	2021	2022	Change
Cash and cash equivalents (as of Dec. 31)	20,281,234	16,548,040	-18.41%
Equity (as of Dec. 31)	22,577,285	18,937,579	-16.12%
Total assets (as of Dec. 31)	23,465,765	19,665,431	-16.20%
Annual loss	-10,371,890	-10,501,695	1.25%
Operating cash flow	-10,337,649	-10,401,429	0.62%
Free Cash Flow	-10,875,721	-10,593,708	-2.59%

not play an active role in the company today, enabled the structuring of an attractively priced offer in the adverse investment environment by selling a portion of their shares at favorable conditions.

InnoMedica will invest the available financial resources in a focused manner to achieve further milestones on the way to market approval and commercialization of the products in oncology and neurology. To this end, current clinical trials will be continued and expanded depending on additional funding. For further financing, InnoMedica plans to conduct a capital increase in the first half of 2023. The terms and conditions of this offering will be communicated following the necessary resolutions of the Board of Directors. The progress of development and maturity of the products also allow InnoMedica to intensify negotiations within the framework of collaboration or licensing with potential partners from pharmaceutical industry in order to assess various financing possibilities.

The financial statements of InnoMedica Holding AG and InnoMedica Schweiz AG as well as the consolidated financial statements are prepared in accordance with the Swiss Code of Obligations (OR). The presentations and methods used in the 2021 financial statements are maintained in 2022. Further information and explanations on the values of the consolidated financial statements can be found in the notes. This annual report includes the audited consolidated fi-

ancial statements and the audited separate financial statements of InnoMedica Holding AG. The audited separate financial statements of InnoMedica Schweiz AG can be provided upon request.

Balance

Cash and cash equivalents as of December 31, 2022 amount to CHF 16,548,040. The proceeds from the capital increase in 2022 in the amount of CHF 6,860,514 were below the operating and investment-related cash flows (free cash flow) in the amount of CHF -10,593,708, resulting in a year-on-year decrease in available cash. The **securities** portfolio remains unchanged at year-end 2022, with price gains and currency effects increasing the value of the securities portfolio from CHF 138,775 in 2021 to CHF 143,540 at year-end 2022.

Property, plant and equipment after depreciation amounts to CHF 2,205,145 at year-end 2022, which is below the previous year's value of CHF 2,515,070 after depreciation of CHF 502,204. The minor investments of CHF 192,279 in property, plant and equipment reflect the fact that the expansion of Cleanroom II in Marly has been completed and only supplementary investments in equipment and automation of filling were made in 2022 in order to implement significantly larger production volumes in the cleanroom according to GMP. Further production scaling steps will become necessary in the existing and, if necessary, new clean-

Listing of Previous Financing Rounds

Financing round	Number of shares	Share price (CHF)	Total capital (CHF)	Total share capital (CHF)	Equity valuation (CHF million)
Capital increases 2013-2021²	4,174,802	1.15-33.90	58,675,429.90	1,417,098.70	465
Capital increase 2022	168,563	40.70	6,860,514.10	16,856.30	576

² Historical share prices are shown split-adjusted with adjustment to the current par value of CHF 0.10

rooms upon market entry or significant expansion of clinical trials and will then require significant investments again.

As in previous years, development expenses resulting from clinical and preclinical activities and the production of drugs required for these activities are not capitalized in the financial year 2022, but are recognized in profit or loss. As part of these development activities, InnoMedica has made significant new progress and created intangible assets. However, applying prudence accounting concept, these will only meet the requirements for assets that can be recognized in the balance sheet when they are marketed in the foreseeable future.


As of the balance sheet date of 2022, InnoMedica has no **current interest-bearing liabilities** and provisions. The **other current receivables and liabilities** relate to the VAT receivables and liabilities of the InnoMedica Group companies for the fourth quarter of 2022. **Prepaid expenses** mainly result from prepayments on investments in clean room equipment and filling automation. These investments will be recognized as assets when the assets become operational.

Accrued liabilities result from obligations to creditors that have been rendered but not yet invoiced at the end of the financial year, in particular obligations to clinical trial contractors, social insurance offices and energy providers. **Accounts payable** relate to invoice amounts that have already been invoiced to InnoMedica.

As part of the capital increase 2022, 168,563 shares were issued. As a result, the nominal **share capital** increased to CHF 1,433,955. The year-end balance of **treasury shares** remains unchanged at 16,217 shares at a book value of CHF 0.25. **Shareholders' equity** decreased by CHF 3,639,706, as the loss of the year, which remained more or less unchanged year-on-year, was offset by fewer subscriptions from the 2022 capital increase.

Balance Sheet Items

in CHF, as of Dec. 31



Income Statement

InnoMedica recorded an **annual loss** of CHF 10,501,695 for the financial year 2022, comparable to the previous year's loss of CHF 10,371,890. Development costs increased to CHF 2,490,223 compared to CHF 2,214,766 in the previous year. This includes direct expenses for clinical trials and costs for the necessary production of drugs. Similarly, depreciation expenses increased to CHF 502,204 in 2022 compared to CHF 292,663 in the previous year. The increase is explained by the discontinuation of the one-time reduction of depreciation in 2021 due to the change of the depreciation method from degressive to linear depreciation.

Following increases in personnel resources in previous years and corresponding increases in **personnel expenses**, there is a slight decrease in the corresponding expenses in 2022. This results from a restrained investment activity in the second half of the financial year after the capital increase, specifically postponing the previously intended personnel expansion. Accordingly, personnel expenses in 2022 in the amount of CHF 6,132,751 are slightly below the personnel expenses in 2021 in the amount of CHF 6,298,170. This decrease also results from lower **other personnel expenses**, which reflect the short-term reduction in the

use of personnel services in the production area. At the end of the year 2022, InnoMedica employed 50 people compared to 51 at the end of the previous year. The headcount throughout the year corresponds to a workforce of 4,739 job percent, compared to 4,373 job percent in the previous year.


Other operating expenses mainly consisted of infrastructure, administration and capital increase costs. These expenses decreased from CHF 1,494,599 in 2021 to CHF 1,320,075 in 2022. The reduction is due to lower administrative costs, which were one-off in the previous year due to the introduction of IFRS accounting, as well as a lower issue tax from capital increase. In contrast, **infrastructure expenses** increased from CHF 436,560 in 2021 to CHF 549,584 in 2022.

Administrative expenses in the amount of CHF 307,878 include auditing costs, accounting costs of the subsidiaries InnoMedica Deutschland GmbH, YAMAZAKI-DDS Co., Ltd. as well as costs of the Annual General

Assembly in 2022. The **capital increase expenses** in the amount of CHF 334,700 include all costs and fees of the capital increase. The expenses are lower than the expenses of the previous year in the amount of CHF 506,938 mainly due to lower issue tax. **IT expenses** decreased from CHF 108,966 in the financial year 2021 to CHF 69,972 in the reporting year. Dr. Peter Halbherr continued to provide a license for the operational ERP software sqlFinance free of charge, thus ensuring cost-effective IT.

Income Statement Items

in CHF



Statement of Shareholders' Equity in CHF

Year	2021	2022
Shareholders' equity as of Jan. 01	17,554,676	22,577,285
Capital increases (Share capital)	45,412	16,856
Change in legal reserves	15,349,087	6,843,658
Shareholders' equity as of Dec. 31 excluding net income	32,949,175	29,437,799
Net income	-10,371,890	-10,501,695
Currency translation differences in CHF	0	1,475
Shareholders' equity as of Dec. 31	22,577,285	18,937,579

Consolidated Financial Statements

InnoMedica Holding AG

Balance Sheet

Year	December 31, 2021	December 31, 2022
Assets	CHF	CHF
Cash and cash equivalents	20,281,234	16,548,040
Securities	138,775	143,540
Other current receivables	242,581	236,124
Prepaid expenses and accrued income	88,105	332,582
Total current assets	20,750,695	17,260,285
Property, plant and equipment	2,515,070	2,205,145
Intangible assets	200,000	200,000
Total fixed assets	2,715,070	2,405,145
Total assets	23,465,765	19,665,431
Liabilities and shareholders' equity	CHF	CHF
Accounts payable	60,452	68,295
Other current liabilities	179,248	159,267
Accrued expenses and deferred income	648,781	500,291
Total current liabilities	888,481	727,852
Total long-term liabilities	-	-
Share capital	1,417,099	1,433,955
Total legal reserves	59,067,820	65,911,478
Reserves from capital contributions	57,049,784	63,669,174
Other legal reserves	2,018,035	2,242,304
Loss carried forward	-27,531,689	-37,903,580
Currency translation differences in CHF	-	1,475
Annual loss	-10,371,890	-10,501,695
Treasury shares	-4,054	-4,054
Total shareholders' equity	22,577,285	18,937,579
Total liabilities and shareholders' equity	23,465,765	19,665,431

Income Statement

Year	2021	2022
Net sales	CHF	CHF
Total net sales	-	-
Cost of materials and services		
Development expenses	-2,214,766	-2,490,223
Total cost of materials and services	-2,214,766	-2,490,223
Personnel expenses		
Wages and salaries	-4,860,641	-4,872,813
Social security expenses	-699,207	-681,588
Other personnel expenses	-738,323	-578,350
Total personnel expenses	-6,298,170	-6,132,751
Other operating expenses		
Infrastructure expenses	-436,560	-549,584
Vehicle and transport expenses	-18,596	-17,763
Property insurance and fees	-11,086	-11,161
Administrative expenses	-386,923	-307,878
Capital increase expenses	-506,938	-334,700
IT expenses	-108,966	-69,972
Advertising expenses	-25,531	-29,016
Total other operating expenses	-1,494,599	-1,320,075
EBITDA	-10,007,535	-9,943,049
Depreciation	-292,663	-502,204
EBIT	-10,300,198	-10,445,252
Financial expenses	-45,422	-18,972
Financial income	913	1,040
Value adjustment on securities	-7,046	4,352
Currency differences	-1,039	-15,738
EBT	-10,352,792	-10,474,571
Direct taxes	-19,098	-27,124
Net income	-10,371,890	-10,501,695



Independence through Nanofactory

Development and production of pharmaceutical products in the company's own infrastructure enable maximum flexibility as well as rapid responsiveness.

Dependence on third parties is minimized while maintaining cost efficiency.



Cash Flow Statement in CHF

Year	2021	2022
Net income	-10,371,890	-10,501,695
Depreciation	292,663	502,204
Change in current assets	-120,798	-242,784
Change in current liabilities	-66,512	-12,139
Change in accrued expenses and deferred income	-71,112	-148,490
Currency translation differences in CHF	-	1,475
Cash flow from operating activities	-10,337,649	-10,401,429
Investments in property, plant and equipment	-538,071	-192,279
Cash flow from investing activities	-538,071	-192,279
Repayments of debt	-240,000	-
Equity contributions	15,394,499	6,860,514
Cash flow from financing activities	15,154,499	6,860,514
Change in cash and cash equivalents	4,278,778	-3,733,194
Cash and cash equivalents as of Jan. 01	16,002,456	20,281,234
Cash and cash equivalents as of Dec. 31	20,281,234	16,548,040
Change in cash and cash equivalents	4,278,778	-3,733,194

Notes to the Consolidated Financial Statements InnoMedica Holding AG 2022

The 2022 consolidated financial statements include the companies of the InnoMedica Group. The scope of consolidation includes the individual companies InnoMedica Holding AG (domiciled in Zug), InnoMedica Schweiz AG (domiciled in Bern), InnoMedica Deutschland GmbH (domiciled in Freiburg i. Br., Germany) and YAMAZAKI-DDS Co., Ltd. (domiciled in Ibaraki, Japan). InnoMedica Schweiz AG, InnoMedica Deutschland GmbH and YAMAZAKI-DDS Co., Ltd. are wholly owned directly by InnoMedica Holding AG. InnoMedica Schweiz AG bundles the operational business of the InnoMedica Group and is linked to InnoMedica Holding AG via a research and development contract. InnoMedica Holding AG is responsible for the strategic management and holds the intellectual property rights as well as the financial resources of the company. The purpose of YAMAZAKI-DDS Co., Ltd. is to hold patents in the field of liposomal drug delivery system. The share capital of YAMAZAKI-DDS Co., Ltd. is 10,000,000 Japanese yen. InnoMedica Deutschland GmbH was founded on 10.05.2022 with the purpose of trade, production, and distribution of medical products in German-speaking and other European countries.

The consolidated financial statements have been prepared in accordance with the provisions of the Swiss Code of Obligations (OR) on commercial accounting and financial reporting. The income statement has been prepared using the nature of expense method and the cash flow from operating activities has been prepared using the indirect method.

Valuation Principles

Securities: Securities are valued at market value at the balance sheet date. Price gains or losses and currency differences are recognized as such in the income statement. These are shares and securities available for sale in the short term and denominated in various currencies. The positions and valuation principles remained unchanged compared to the previous year.

Property, plant and equipment: Property, plant and equipment are recorded at acquisition cost minus depreciation. Since 2021, property, plant and equipment have been depreciated using linear depreciation based on the useful life of the individual assets. In previous financial years, property, plant and equipment were depreciated using the declining balance method at a rate of 20% based on the value of the respective

previous year. The change in the depreciation method resulted in a one-time cumulative effect from the book value adjustment on expenses of CHF 205,144 at the beginning of the financial year 2021. The depreciation of the financial year 2021 when applying linear depreciation without taking this effect into account amounted to CHF 497,807. The depreciation of the financial year 2022 amounts to CHF 502,204. The property, plant and equipment consists of machines and equipment from laboratory, production and analytical departments, as well as three vehicles and various office equipment.

Classifications and Explanations

Accruals and deferrals: Accruals and deferrals include prepayments for investments in cleanroom equipment and filling automation on the assets side. On the liabilities side, costs already incurred and accruals for services received but not yet invoiced are recorded.

OTC stock brokerage: InnoMedica brings together interested parties for the purchase and sale of InnoMedica shares. InnoMedica makes itself available as administrator of the assets until the transaction is completed. In return, it charges an expense allowance for personnel expenses in the form of a transaction fee.

Reserves from capital contributions: The reserves from capital contributions as of December 31, 2020 (in the amount of CHF 41,789,370.85 according to the individual financial statements of InnoMedica Holding AG) have been recognized by the Swiss Federal Tax Administration (FTA) in this amount. Additional reserves from capital contributions 2021 and 2022 will be declared after the audit of the financial statements 2022.

Treasury shares: At the balance sheet date of 2022, 14'339'550 shares were placed compared to 14'170'987 shares in the previous year. There are unchanged 16'217 shares in the possession of InnoMedica. The treasury shares are valued at the effectively paid purchase price of CHF 0.25 as of the balance sheet date. Gains from the sale of treasury shares are recognized as other legal reserves.

Financial expenses and income: Financial expenses for the financial years 2021 and 2022 include bank inte-

rest and charges. Costs for the capital increase are reported separately. Financial income includes dividends.

Capital increase expenses: The position is shown including issue tax of CHF 152,401 for 2021 and CHF 67,912 for 2022.

Additional Information

Annual average of job percent: InnoMedica employed an annual average of 51.5 people in 2022. The work volume amounted to an annual average of 4,739 job percent (comparison 2021: 48 employees with an annual average of 4,373 job percent). With the exception of four members of the management of InnoMedica Holding AG (395 job percent) and one employee of InnoMedica Deutschland GmbH (22 job percent), the employees are employed by InnoMedica Schweiz AG.

Trust shares: In addition to treasury shares, InnoMedica holds 3,607,850 shares of InnoMedica Holding AG in trust as of the end of 2022. In the previous year, there were 3,595,979 shares.

Remuneration of board members: The remuneration of CHF 10,000 per year per person for members of the Board of Directors is paid by resolution of the Board of Directors for the period between the annual general meetings. For the period 2022/2023, an honorarium in the amount of CHF 5,000 per person and a total of CHF 20,000 was accrued in favor of the Board of Directors. This corresponds to the previous year's practice.

Significant shareholders: On the balance sheet date of 2022, Dr. Peter Halbherr held 2,652,335 shares (18.5 percent of 14,339,550 shares). No other shareholder held more than 5 percent of the shares on December 31, 2022. In the previous financial year, Dr. Peter Halbherr held 2,652,335 shares (18.7 percent of 14,170,987 shares) and Dr. Herbert Früh 706,842 shares (5.0 percent). No other shareholder held more than 5 percent of the shares on December 31, 2021.

Business transactions with related parties: Business transactions with related parties are based on standard contractual forms and are concluded at market conditions. InnoMedica uses the ERP software sqlFinance to execute various operational processes. Dr. Peter Halbherr developed the software and privately holds all property rights. InnoMedica has entered into a license agreement for the software with Dr. Peter Halbherr. According to the license agreement, InnoMedica receives a free license for the use of the software until December 31, 2022. No other transactions with related parties took place in the reporting period.

Events after the balance sheet date: There are no events after the balance sheet date that require recognition and would have a material impact on the annual financial statements.

Obligations from long-term contracts: InnoMedica Holding AG has entered into a long-term lease agreement with the Marly Innovation Center (MIC). This can be terminated unilaterally by InnoMedica with a notice period of 2 years and at the end of a quarter. This results in a rental obligation of a maximum of 27 monthly rents of CHF 18,950 each (total CHF 511,650) as of December 31, 2022. As of December 31, 2021, the rental obligation of a maximum of 27 monthly rents amounted to CHF 18,368 each (total CHF 495,945).

Social security obligations: Social security obligations amount to CHF 45,678 at year-end 2022 compared to CHF 107,325 in the previous year.

Auditor's fee: The auditor's fee amounts to CHF 68,000 plus VAT for the audit of the annual reporting of the Group and the individual companies InnoMedica Holding AG and InnoMedica Schweiz AG according to the Swiss Code of Obligations (OR) and International Financial Reporting Standards (IFRS). In the previous year, the fee was CHF 65,000 plus VAT.

Report of the statutory auditor

to the General Meeting of InnoMedica Holding AG, Zug

Report on the audit of the consolidated financial statements

Opinion

We have audited the consolidated financial statements of InnoMedica Holding AG and its subsidiaries (the Group), which comprise the consolidated balance sheet as at 31 December 2022, and the consolidated income statement for the year then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies.

In our opinion, the consolidated financial statements (page 12, 13, 16, 17 and 18) comply with Swiss law and the consolidation and valuation principles described in the notes.

Basis for opinion

We conducted our audit in accordance with Swiss law and Swiss Standards on Auditing (SA-CH). Our responsibilities under those provisions and standards are further described in the 'Auditor's responsibilities for the audit of the consolidated financial statements' section of our report. We are independent of the Group in accordance with the provisions of Swiss law and the requirements of the Swiss audit profession, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other information

The Board of Directors is responsible for the other information. The other information comprises the information included in the annual report, but does not include the financial statements, the consolidated financial statements and our auditor's reports thereon.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Board of Directors' responsibilities for the consolidated financial statements

The Board of Directors is responsible for the preparation of the consolidated financial statements in accordance with the provisions of Swiss law, and for such internal control as the Board of Directors determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, the Board of Directors is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the consolidated financial statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion.



PricewaterhouseCoopers AG, Birchstrasse 160, Postfach, 8050 Zürich, Switzerland
Telefon: +41 58 792 44 00, www.pwc.ch

PricewaterhouseCoopers AG is a member of the global PricewaterhouseCoopers network of firms, each of which is a separate and independent legal entity.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Swiss law and SA-CH will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with Swiss law and SA-CH, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with the Board of Directors or its relevant committee regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Report on other legal and regulatory requirements

In accordance with article 728a paragraph 1 item 3 CO and PS-CH 890, we confirm that an internal control system exists which has been designed for the preparation of the consolidated financial statements according to the instructions of the Board of Directors.

We recommend that the consolidated financial statements submitted to you be approved.

PricewaterhouseCoopers AG



Hanspeter Gerber
Licensed audit expert
Auditor in charge



Andreas Scheibli
Licensed audit expert

Zürich, 31 January 2023



Annual Financial Statements

InnoMedica Holding AG

Balance Sheet

Year	December 31, 2021	December 31, 2022
Assets	CHF	CHF
Cash and cash equivalents	14,339,769	11,256,082
Securities	138,775	143,540
Other current receivables	237,795	231,338
Total current assets	14,716,339	11,630,960
Loans to Group companies	4,000,000	4,000,000
Subsidiaries ³	2,269,768	2,467,308
Total fixed assets	6,269,768	6,467,308
Total assets	20,986,108	18,098,268
Liabilities and shareholders' equity	CHF	CHF
Accounts payable	17,720	4,935
Liabilities to Group companies	1,391,734	3,385,701
Accrued expenses and deferred income	96,100	91,804
Total current liabilities	1,505,554	3,482,440
Total non-current liabilities	-	-
Share capital	1,417,099	1,433,955
Total legal reserves	59,156,493	66,000,151
Reserves from capital contributions	57,138,458	63,757,847
Other legal reserves	2,018,035	2,242,304
Loss carried forward	-29,049,029	-41,088,984
Annual loss	-12,039,956	-11,725,239
Treasury shares	-4,054	-4,054
Total shareholders' equity	19,480,553	14,615,828
Total liabilities and shareholders' equity	20,986,108	18,098,268

³ See notes in Appendix P 24.

Income Statement

Year	2021	2022
Net sales	CHF	CHF
Total net sales	-	-
Cost of materials and services		
Development expenses	-10,385,083	-10,350,248
Total cost of materials and services	-10,385,083	-10,350,248
Personnel expenses		
Wages and salaries	-807,925	-744,905
Social security expenses	-96,589	-90,601
Other personnel expenses	-57,984	-41,777
Total personnel expenses	-962,498	-877,283
Other operating expenses		
Administrative expenses	-223,396	-219,773
Capital increase expenses	-506,938	-334,700
Advertising expenses	-10,656	-17,188
Total other operating expenses	-740,989	-571,661
EBITDA / EBIT	-12,088,571	-11,799,192
Financial expenses	-43,906	-13,401
Financial income	100,913	101,040
Value adjustment on securities	-7,046	4,352
Currency differences	3,040	-1,707
EBT	-12,035,571	-11,708,909
Capital taxes	-4,385	-16,331
Net income	-12,039,956	-11,725,239

Cash Flow Statement in CHF

Year	2021	2022
Net income	-12,039,956	-11,725,239
Change in current assets	-40,175	1,692
Change in current liabilities	-312,865	1,981,182
Change in accrued expenses and deferred income	34,096	-4,296
Cash flow from operating activities	-12,358,900	-9,746,662
Investments in subsidiaries	-	-197,539
Cash flow from investing activities	-	-197,539
Repayments of debt	-240,000	-
Equity contributions	15,394,499	6,860,514
Cash flow from financing activities	15,154,499	6,860,514
Change in cash and cash equivalents	2,795,599	-3,083,687
Cash and cash equivalents as of Jan. 01	11,544,171	14,339,769
Cash and cash equivalents as of Dec. 31	14,339,769	11,256,082
Change in cash and cash equivalents	2,795,599	-3,083,687



Notes to the Financial Statements InnoMedica Holding AG 2022

The 2022 financial statements of InnoMedica Holding AG comprise the separate financial statements of InnoMedica's parent company. InnoMedica Holding AG is a 100 percent shareholder of InnoMedica Schweiz AG, YAMAZAKI-DDS Co., Ltd and InnoMedica Deutschland GmbH. InnoMedica Schweiz AG bundles the operating business of the InnoMedica Group and is linked to InnoMedica Holding AG via a research and development contract. The purpose of YAMAZAKI-DDS Co., Ltd. is to hold patents in the field of liposomal drug delivery system. The share capital of YAMAZAKI-DDS Co., Ltd. is 10,000,000 Japanese yen. InnoMedica Deutschland GmbH was founded on 10.05.2022 with the purpose of trade, production, and distribution of medical products in German-speaking and other European countries.

The financial statements have been prepared in accordance with the provisions of the Swiss Code of Obligations (OR) on commercial accounting and financial reporting. The income statement is prepared using the nature of expense method and the cash flow from operating activities is prepared using the indirect method. Further notes to the financial statements of InnoMedica Holding AG (valuation principles, classifications and explanations as well as additional information) can be found in the notes to the consolidated financial statements of InnoMedica Holding AG (see P 17/P 18).

Classifications and Explanations

Subsidiaries: The subsidiaries include YAMAZAKI-DDS Co., Ltd. (domiciled in Ibaraki, Japan), InnoMedica Schweiz AG (domiciled in Bern) and InnoMedica Deutschland GmbH (domiciled in Freiburg i. Br., Germany). The investment in YAMAZAKI-DDS Co., Ltd. continues to be valued at CHF 200,000 and comprises intellectual property assets (patents) in the nanomedicine field. The investment in InnoMedica Schweiz AG is valued at the amortized cost of CHF 188,673 plus the value of the transferred assets of CHF 1,881,095. The investment in InnoMedica Deutschland GmbH is valued at historical cost of CHF 97,920 (EUR 100,000) in share capital and CHF 99,619 (EUR 100,000) in additional paid-in capital.

Carrying Forward of Net Loss

The loss of CHF 11,725,239 is added to the loss carried forward of CHF 41,088,984 and the balance is transferred to the new account.

Report of the statutory auditor

to the General Meeting of InnoMedica Holding AG, Zug

Report on the audit of the financial statements

Opinion

We have audited the financial statements of InnoMedica Holding AG (the Company), which comprise the balance sheet as at 31 December 2022, and the income statement, the cash flow statement for the year then ended, and notes to the financial statements.

In our opinion, the financial statements (page 21 to 24) comply with Swiss law and the company's articles of incorporation.

Basis for opinion

We conducted our audit in accordance with Swiss law and Swiss Standards on Auditing (SA-CH). Our responsibilities under those provisions and standards are further described in the 'Auditor's responsibilities for the audit of the financial statements' section of our report. We are independent of the Company in accordance with the provisions of Swiss law and the requirements of the Swiss audit profession, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other information

The Board of Directors is responsible for the other information. The other information comprises the information included in the annual report, but does not include the financial statements, the consolidated financial statements and our auditor's reports thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Board of Directors' responsibilities for the financial statements

The Board of Directors is responsible for the preparation of the financial statements in accordance with the provisions of Swiss law and the company's articles of incorporation, and for such internal control as the Board of Directors determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with



PricewaterhouseCoopers AG, Birchstrasse 160, Postfach, 8050 Zürich, Switzerland
Telefon: +41 58 792 44 00, www.pwc.ch

PricewaterhouseCoopers AG is a member of the global PricewaterhouseCoopers network of firms, each of which is a separate and independent legal entity.

Swiss law and SA-CH will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with Swiss law and SA-CH, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

We communicate with the Board of Directors or its relevant committee regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Report on other legal and regulatory requirements

In accordance with article 728a paragraph 1 item 3 CO and PS-CH 890, we confirm that an internal control system exists which has been designed for the preparation of the financial statements according to the instructions of the Board of Directors.

We further confirm that the proposed carry forward of the accumulated losses complies with Swiss law and the company's articles of incorporation. We recommend that the financial statements submitted to you be approved.

PricewaterhouseCoopers AG



Hanspeter Gerber
Licensed audit expert
Auditor in charge



Andreas Scheibli
Licensed audit expert

Zürich, 31 January 2023

General Information

Business idea	InnoMedica is developing a new generation of drugs based on an innovative liposomal transport system that influences the distribution of active ingredients in the body and aims to improve the biodistribution of known active ingredients. In January 2013, InnoMedica Holding AG launched a first project in oncology, which is now in clinical trials. A second project in neurology aims to use liposomes to treat neurodegenerative diseases. In addition, the patented technology platform is also to be used in other indications, such as arteriosclerosis or in the treatment of bacterial toxins without the use of antibiotics, as well as in diagnostics and infectiology.
Corporation	InnoMedica comprises the companies InnoMedica Holding AG (parent company), InnoMedica Schweiz AG, InnoMedica Deutschland GmbH (domiciled in Freiburg, Germany) and YAMAZAKI-DDS Co., Ltd. (domiciled in Ibaraki, Japan).
Board of Directors	Dr. Peter Halbherr (Chairman), Dr. Denis Bron (Vice Chairman), Dr. Noboru Yamazaki, Prof. Dr. Urs Wälchli.

More Information on InnoMedica Holding AG:

Legal structure	Public limited company
Founded	June 05, 2000
Shares outstanding	14,339,550 registered shares at CHF 0.10 par value
Listing/Trading	OTC via Investor Relations, Mrs. Andrea Zurkirchen
Security number	55.897.390
ISIN number	CH0558973902
Investor Relations	Mrs. Andrea Zurkirchen, phone +41 (0)44 383 88 22
Headquarter	InnoMedica Holding AG, Baarerstrasse 34, CH-6300 Zug
Website	www.innomedica.com
E-mail	info@innomedica.com

This annual report contains certain forward-looking statements. These may be identified by statements containing the words "should", "assume", "expect", "anticipate", "intend" or similar expressions and phrases. Actual future results could differ substantially from those contained in forward-looking statements due to various factors, including legal and regulatory developments, foreign exchange rate fluctuations, changes in market conditions and in the activities of competitors, failure to launch or delay in launching new products for various reasons, risks related to new product development, production hold-ups, loss of or inability to obtain intellectual property rights, legal disputes and proceedings, adverse publicity and media coverage.

InnoMedica Holding AG

Zug - Switzerland

InnoMedica Schweiz AG
Gesellschaftsstrasse 16
CH-3012 Bern

Contact
+41 (0)44 383 88 22
info@innomedica.com
www.innomedica.com

The English version of InnoMedica,s Annual Report
2022 was translated from the original German
version which shall be binding in case of disparities.